Arcus Biosciences Inc. Stock Prediction and Forecast [RCUS]

AI-generated source summary

Arqus Biosciences Inc. (RCUS) stock exhibits a strong rising trend with positive signals from both short and long-term moving averages. The stock is currently trading at $23.18, indicating it is overvalued. Analysts have assigned it a 'Strong Buy Candidate' rating with a target price of $30.311 and a stop-loss set at $22.39 (-3.40%). The stock has shown medium daily movements, contributing to a medium risk profile. The RSI is at 80, further increasing risk. A buy signal was identified from a pivot bottom 11 days ago, and the stock has since risen 20.04% with increasing volume. In the short term, a potential dip to the support level of $20.35 is anticipated, with further gains expected in the next three months. However, breaches below $20.99 and $18.61 would indicate sell signals. Longer-term, the stock is projected to increase by 43.74% to $33.18. The P/E ratio is -7.07, suggesting potential for bankruptcy. Insider trading data shows a net sell-off, with a significant insider power score of 82.637, indicating substantial insider buying over the last 100 transactions.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   25 Nov 2025, 04:45 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   02 Jul 2026, 02:13 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   02 Jul 2026, 02:13 UTC

   All evaluable predictions in this case reached terminal outcomes.